Imalia reports initial proof-of-concept data for the effect of IMA001,on the progression of markers of sickle cell disease (SCD) in the Townes HbSS experimental mouse model. IMA001administered at 185 mg/kg/day for up to 28 days, improves the critical hematological markers of SCD (e.g. hemoglobin level, hematocrit, Red blood cell (RBC) and reticulocyte counts…), reduces sickling and increases RBC half-life in the circulation. This feature on anemia alleviation has a direct physiological effect in the Townes mice, through mitigation in spleen size indicating a positive impact on stress erythropoiesis.
Imalia to Present Two Abstracts at the 66th American Society of Hematology Annual Meeting
Imalia will present two abstracts at the 66th meeting of the American Society of